Share

Llovet, Josep M. us

List of all publications

Publishing since 1991 (Senior)

    2010

  1. Journal Article Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY, Solé M, Thung S, Moyano S, Toffanin S, Mínguez B, Cabellos L, Peix J, Schwartz M, Mazzaferro V, Bruix J, Llovet JM. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.  J. Hepatol.  2010;52;4  Link to IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.
  2. CommentJournal Article Toffanin S, Villanueva A, Llovet JM. miRNA delivery: emerging therapy for hepatocellular carcinoma.  Gastroenterology  2010;138;3  Link to miRNA delivery: emerging therapy for hepatocellular carcinoma.
  3. Journal ArticleResearch Support, N.I.H., Extramural Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.  Semin. Liver Dis.  2010;30;1  Link to Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
  4. Journal Article Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.  Semin. Liver Dis.  2010;30;1  Link to Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.
  5. Introductory Journal Article Bruix J, Llovet JM. Two decades of advances in hepatocellular carcinoma research.  Semin. Liver Dis.  2010;30;1  Link to Two decades of advances in hepatocellular carcinoma research.
  6. Journal ArticleResearch Support, N.I.H., Extramural Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.  Annu. Rev. Med.  2010;61  Link to Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.

    7. 2009

  7. CommentJournal ArticleResearch Support, N.I.H., Extramural Villanueva A, Savic R, Llovet JM. Lymphotoxins: new targets for hepatocellular carcinoma.  Cancer Cell  2009;16;4  Link to Lymphotoxins: new targets for hepatocellular carcinoma.
  8. Journal ArticleResearch Support, N.I.H., Extramural Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, Savic R, Hoshida Y, Lim KH, Melgar-Lesmes P, Yea S, Peix J, Deniz K, Fiel MI, Thung S, Alsinet C, Tovar V, Mazzaferro V, Bruix J, Roayaie S, Schwartz M, Friedman SL, Llovet JM. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.  J. Hepatol.  2009;51;4  Link to Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
  9. Journal ArticleResearch Support, N.I.H., Extramural Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, Villanueva A, Newell P, Ikeda K, Hashimoto M, Watanabe G, Gabriel S, Friedman SL, Kumada H, Llovet JM, Golub TR. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.  Cancer Res.  2009;69;18  Link to Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.
  10. Journal Article Zhu AX, El-Khoueiry A, Llovet JM. Accomplishments in 2008 in the management of hepatobiliary cancers.  Gastrointestinal cancer research : GCR  2009;3;5 Supplement 2  Link to Accomplishments in 2008 in the management of hepatobiliary cancers.
  11. Journal ArticleResearch Support, N.I.H., Extramural Roayaie S, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, Labow DM, Llovet JM, Schwartz ME. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma.  Gastroenterology  2009;137;3  Link to A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma.
  12. CommentLetterReview Forner A, Llovet JM, Bruix J. Sunitinib and the benefits of a negative study.  Lancet Oncol.  2009;10;8  Link to Sunitinib and the benefits of a negative study.
  13. Journal ArticleResearch Support, N.I.H., Extramural Seki E, De Minicis S, Gwak GY, Kluwe J, Inokuchi S, Bursill CA, Llovet JM, Brenner DA, Schwabe RF. CCR1 and CCR5 promote hepatic fibrosis in mice.  J. Clin. Invest.  2009;119;7  Link to CCR1 and CCR5 promote hepatic fibrosis in mice.
  14. Journal ArticleResearch Support, N.I.H., Extramural Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, O'Sullivan M, Lu J, Phillips LA, Lockhart VL, Shah SP, Tanwar PS, Mermel CH, Beroukhim R, Azam M, Teixeira J, Meyerson M, Hughes TP, Llovet JM, Radich J, Mullighan CG, Golub TR, Sorensen PH, Daley GQ. Lin28 promotes transformation and is associated with advanced human malignancies.  Nat. Genet.  2009;41;7  Link to Lin28 promotes transformation and is associated with advanced human malignancies.
  15. Comparative StudyJournal ArticleMulticenter StudyResearch Support, N.I.H., Extramural Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S, Schwartz M. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.  Gastroenterology  2009;137;1  Link to Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.
  16. Journal ArticleReview Mínguez B, Tovar V, Chiang D, Villanueva A, Llovet JM. Pathogenesis of hepatocellular carcinoma and molecular therapies.  Curr. Opin. Gastroenterol.  2009;25;3  Link to Pathogenesis of hepatocellular carcinoma and molecular therapies.
  17. Editorial Hoshida Y, Villanueva A, Llovet JM. Molecular profiling to predict hepatocellular carcinoma outcome.  Expert review of gastroenterology & hepatology  2009;3;2  Link to Molecular profiling to predict hepatocellular carcinoma outcome.
  18. Journal ArticleResearch Support, N.I.H., Extramural Yoo BK, Emdad L, Su ZZ, Villanueva A, Chiang DY, Mukhopadhyay ND, Mills AS, Waxman S, Fisher RA, Llovet JM, Fisher PB, Sarkar D. Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression.  J. Clin. Invest.  2009;119;3  Link to Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression.
  19. Consensus Development ConferenceJournal Article Forner A, Ayuso C, Isabel Real M, Sastre J, Robles R, Sangro B, Varela M, de la Mata M, Buti M, Martí-Bonmatí L, Bru C, Tabernero J, Llovet JM, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma]  Med Clin (Barc)  2009;132;7  Link to [Diagnosis and treatment of hepatocellular carcinoma]
  20. Journal Article Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma.  Lancet  2009;373;9664  Link to Major achievements in hepatocellular carcinoma.
  21. CommentEditorialResearch Support, N.I.H., Extramural Llovet JM, Bruix J. Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials.  J. Clin. Oncol.  2009;27;6  Link to Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials.
  22. Comparative StudyEvaluation StudiesJournal Article Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ, de Lope CR, Reig M, Bianchi L, Llovet JM, Bruix J. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?  Cancer  2009;115;3  Link to Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?
  23. Journal Article Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.  Lancet Oncol.  2009;10;1  Link to Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.

    24. 2008

  24. Comparative StudyJournal ArticleMulticenter StudyResearch Support, N.I.H., Extramural Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM. Pivotal role of mTOR signaling in hepatocellular carcinoma.  Gastroenterology  2008;135;6  Link to Pivotal role of mTOR signaling in hepatocellular carcinoma.
  25. Journal ArticleResearch Support, N.I.H., Extramural Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR. Gene expression in fixed tissues and outcome in hepatocellular carcinoma.  N. Engl. J. Med.  2008;359;19  Link to Gene expression in fixed tissues and outcome in hepatocellular carcinoma.
  26. Journal ArticleResearch Support, N.I.H., ExtramuralReview Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma.  Hepatology  2008;48;4  Link to Molecular targeted therapies in hepatocellular carcinoma.
  27. Journal ArticleResearch Support, N.I.H., Extramural Schwartz M, Dvorchik I, Roayaie S, Fiel MI, Finkelstein S, Marsh JW, Martignetti JA, Llovet JM. Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers.  J. Hepatol.  2008;49;4  Link to Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers.
  28. CommentEditorialResearch Support, N.I.H., Extramural Llovet JM, Lok A. Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma.  J. Natl. Cancer Inst.  2008;100;16  Link to Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma.
  29. Journal ArticleResearch Support, N.I.H., Extramural Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, LeBlanc AC, Donovan DJ, Thung SN, Solé M, Tovar V, Alsinet C, Ramos AH, Barretina J, Roayaie S, Schwartz M, Waxman S, Bruix J, Mazzaferro V, Ligon AH, Najfeld V, Friedman SL, Sellers WR, Meyerson M, Llovet JM. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.  Cancer Res.  2008;68;16  Link to Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.
  30. Clinical Trial, Phase IIIJournal ArticleMulticenter StudyRandomized Controlled Trial Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma.  N. Engl. J. Med.  2008;359;4  Link to Sorafenib in advanced hepatocellular carcinoma.
  31. Journal ArticleResearch Support, N.I.H., ExtramuralReview Villanueva A, Toffanin S, Llovet JM. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps.  Curr Opin Oncol  2008;20;4  Link to Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps.
  32. CommentEditorialResearch Support, N.I.H., Extramural Newell P, Villanueva A, Llovet JM. Molecular targeted therapies in hepatocellular carcinoma: from pre-clinical models to clinical trials.  J. Hepatol.  2008;49;1  Link to Molecular targeted therapies in hepatocellular carcinoma: from pre-clinical models to clinical trials.
  33. Journal ArticleResearch Support, N.I.H., ExtramuralReview Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ. Design and endpoints of clinical trials in hepatocellular carcinoma.  J. Natl. Cancer Inst.  2008;100;10  Link to Design and endpoints of clinical trials in hepatocellular carcinoma.
  34. Comparative StudyJournal ArticleResearch Support, N.I.H., Extramural Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E, Villanueva A, Loke J, Tarocchi M, Akita K, Shirasawa S, Sasazuki T, Martignetti JA, Llovet JM, Friedman SL. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma.  Gastroenterology  2008;134;5  Link to Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma.
  35. Journal ArticleResearch Support, N.I.H., ExtramuralReview Newell P, Villanueva A, Friedman SL, Koike K, Llovet JM. Experimental models of hepatocellular carcinoma.  J. Hepatol.  2008;48;5  Link to Experimental models of hepatocellular carcinoma.
  36. Journal ArticleResearch Support, N.I.H., ExtramuralReview Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008.  J. Hepatol.  2008;48 Suppl 1  Link to Novel advancements in the management of hepatocellular carcinoma in 2008.
  37. Clinical TrialJournal ArticleResearch Support, N.I.H., ExtramuralValidation Studies Forner A, Vilana R, Ayuso C, Bianchi L, Solé M, Ayuso JR, Boix L, Sala M, Varela M, Llovet JM, Brú C, Bruix J. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.  Hepatology  2008;47;1  Link to Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

    38. 2007

  38. Journal ArticleReview Llovet JM. Clinical and molecular classification of hepatocellular carcinoma.  Liver Transpl.  2007;13;11 Suppl 2  Link to Clinical and molecular classification of hepatocellular carcinoma.
  39. Journal ArticleMulticenter Study Bräu N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, Trikha A, Sherman M, Sulkowski MS, Dieterich DT, Rigsby MO, Wright TL, Hernandez MD, Jain MK, Khatri GK, Sterling RK, Bonacini M, Martyn CA, Aytaman A, Llovet JM, Brown ST, Bini EJ. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study.  J. Hepatol.  2007;47;4  Link to Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study.
  40. English AbstractJournal ArticleReview Tovar V, Villanueva A, Llovet JM. [Cell biology and genetics in liver cancer]  Gastroenterol Hepatol  2007;30;6  Link to [Cell biology and genetics in liver cancer]
  41. Journal ArticleResearch Support, N.I.H., Extramural Kremer-Tal S, Narla G, Chen Y, Hod E, DiFeo A, Yea S, Lee JS, Schwartz M, Thung SN, Fiel IM, Banck M, Zimran E, Thorgeirsson SS, Mazzaferro V, Bruix J, Martignetti JA, Llovet JM, Friedman SL. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation.  J. Hepatol.  2007;46;4  Link to Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation.
  42. Journal ArticleResearch Support, N.I.H., Extramural Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, Fiel I, Thung S, Mazzaferro V, Bruix J, Bottinger E, Friedman S, Waxman S, Llovet JM. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma.  Hepatology  2007;45;4  Link to Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma.
  43. Clinical TrialJournal Article Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, Castells L, Montañá X, Llovet JM, Bruix J. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.  J. Hepatol.  2007;46;3  Link to Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.
  44. Journal ArticleResearch Support, N.I.H., ExtramuralReview Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma.  Semin. Liver Dis.  2007;27;1  Link to Genomics and signaling pathways in hepatocellular carcinoma.

    45. 2006

  45. Journal ArticleMulticenter StudyRandomized Controlled Trial Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G, Tagger A, Colombo M, Bonino F, Majno P, Llovet JM. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis.  Hepatology  2006;44;6  Link to Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis.
  46. Journal ArticleResearch Support, N.I.H., Extramural Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, Schwartz M, Thung SN, Khitrov G, Zhang W, Villanueva A, Battiston C, Mazzaferro V, Bruix J, Waxman S, Friedman SL. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.  Gastroenterology  2006;131;6  Link to A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.
  47. Journal ArticleReview Lopez PM, Villanueva A, Roayaie S, Llovet JM. Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal.  Liver Transpl.  2006;12;12  Link to Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal.
  48. CommentEditorial Llovet JM. Expanding HCC criteria for liver transplant: the urgent need for prospective, robust data.  Liver Transpl.  2006;12;12  Link to Expanding HCC criteria for liver transplant: the urgent need for prospective, robust data.
  49. Journal ArticleResearch Support, N.I.H., ExtramuralReview Lemmer ER, Friedman SL, Llovet JM. Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: the potential of gene expression profiling.  Semin. Liver Dis.  2006;26;4  Link to Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: the potential of gene expression profiling.
  50. CommentJournal Article Llovet JM, Schwartz M, Fuster J, Bruix J. Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there.  Semin. Liver Dis.  2006;26;3  Link to Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there.
  51. Journal ArticleReview Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma.  Oncogene  2006;25;27  Link to New aspects of diagnosis and therapy of hepatocellular carcinoma.
  52. Journal ArticleMeta-AnalysisReview Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials.  Aliment. Pharmacol. Ther.  2006;23;11  Link to Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials.
  53. CommentEditorial Fattovich G, Llovet JM. Risk factors for hepatocellular carcinoma in HCV-cirrhosis: what we know and what is missing.  J. Hepatol.  2006;44;6  Link to Risk factors for hepatocellular carcinoma in HCV-cirrhosis: what we know and what is missing.
  54. Case ReportsJournal Article Llovet JM. Hepatocellular carcinoma: patients with increasing alpha-fetoprotein but no mass on ultrasound.  Clin. Gastroenterol. Hepatol.  2006;4;1  Link to Hepatocellular carcinoma: patients with increasing alpha-fetoprotein but no mass on ultrasound.

    55. 2005

  55. CommentEditorial Lencioni R, Llovet JM. Percutaneous ethanol injection for hepatocellular carcinoma: alive or dead?  J. Hepatol.  2005;43;3  Link to Percutaneous ethanol injection for hepatocellular carcinoma: alive or dead?
  56. Journal Article Rimola A, Llovet JM, Navasa M, Bruix J, Londoño MC, Fuster J, García-Valdecasas JC. Applicability of adult-to-adult living donor liver transplantation.  J. Hepatol.  2005;43;1  Link to Applicability of adult-to-adult living donor liver transplantation.
  57. Comparative StudyJournal ArticleReview Roayaie S, Llovet JM. Liver transplantation for hepatocellular carcinoma: is expansion of criteria justified?  Clin Liver Dis  2005;9;2  Link to Liver transplantation for hepatocellular carcinoma: is expansion of criteria justified?
  58. Journal ArticleReview Llovet JM, Sala M. Non-surgical therapies of hepatocellular carcinoma.  Eur J Gastroenterol Hepatol  2005;17;5  Link to Non-surgical therapies of hepatocellular carcinoma.
  59. Journal ArticleReview Llovet JM. Updated treatment approach to hepatocellular carcinoma.  J. Gastroenterol.  2005;40;3  Link to Updated treatment approach to hepatocellular carcinoma.
  60. Journal ArticleReview Fuster J, Charco R, Llovet JM, Bruix J, García-Valdecasas JC. Liver transplantation in hepatocellular carcinoma.  Transpl. Int.  2005;18;3  Link to Liver transplantation in hepatocellular carcinoma.
  61. Journal Article Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma.  HPB (Oxford)  2005;7;1  Link to Staging systems in hepatocellular carcinoma.
  62. Journal ArticleResearch Support, N.I.H., ExtramuralResearch Support, U.S. Gov't, P.H.S.Review Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma.  Semin. Liver Dis.  2005;25;2  Link to Resection and liver transplantation for hepatocellular carcinoma.

    63. 2004

  63. Journal Article Sala M, Llovet JM, Vilana R, Bianchi L, Solé M, Ayuso C, Brú C, Bruix J. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma.  Hepatology  2004;40;6  Link to Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma.
  64. Journal Article Llovet JM. Treatment of Hepatocellular Carcinoma.  Curr Treat Options Gastroenterol  2004;7;6  Link to Treatment of Hepatocellular Carcinoma.
  65. Journal ArticleReview Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma.  Gastroenterology  2004;127;5 Suppl 1  Link to Chemoembolization for hepatocellular carcinoma.
  66. Journal Article Ayuso JR, Ayuso C, Bombuy E, De Juan C, Llovet JM, De Caralt TM, Sánchez M, Pagés M, Bruix J, García-Valdecasas JC. Preoperative evaluation of biliary anatomy in adult live liver donors with volumetric mangafodipir trisodium enhanced magnetic resonance cholangiography.  Liver Transpl.  2004;10;11  Link to Preoperative evaluation of biliary anatomy in adult live liver donors with volumetric mangafodipir trisodium enhanced magnetic resonance cholangiography.
  67. Journal Article Sala M, Fuster J, Llovet JM, Navasa M, Solé M, Varela M, Pons F, Rimola A, García-Valdecasas JC, Brú C, Bruix J. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation.  Liver Transpl.  2004;10;10  Link to High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation.
  68. Comparative StudyJournal Article Garcia-Retortillo M, Forns X, Llovet JM, Navasa M, Feliu A, Massaguer A, Bruguera M, Fuster J, Garcia-Valdecasas JC, Rimola A. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation.  Hepatology  2004;40;3  Link to Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation.
  69. Journal ArticleReview Pons F, Llovet JM. Approaching focal liver lesions.  Rev Esp Enferm Dig  2004;96;8  Link to Approaching focal liver lesions.
  70. CommentEditorialReview Llovet JM, Wurmbach E. Gene expression profiles in hepatocellular carcinoma: not yet there.  J. Hepatol.  2004;41;2  Link to Gene expression profiles in hepatocellular carcinoma: not yet there.
  71. Clinical TrialJournal ArticleRandomized Controlled Trial Fuster J, Llovet JM, Garcia-Valdecasas JC, Grande L, Fondevila C, Vilana R, Palacin J, Tabet J, Ferrer J, Bruix J, Visa J. Abdominal drainage after liver resection for hepatocellular carcinoma in cirrhotic patients: a randomized controlled study.  Hepatogastroenterology  2004;51;56  Link to Abdominal drainage after liver resection for hepatocellular carcinoma in cirrhotic patients: a randomized controlled study.
  72. Journal ArticleReview Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma.  Cancer Cell  2004;5;3  Link to Focus on hepatocellular carcinoma.
  73. Journal ArticleReview Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.  Liver Transpl.  2004;10;2 Suppl 1  Link to The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.
  74. CommentLetter Llovet JM, Bruix J. Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization.  Radiology  2004;230;1  Link to Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization.

    75. 2003

  75. Journal ArticleReview Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma.  Lancet  2003;362;9399  Link to Hepatocellular carcinoma.
  76. English AbstractJournal Article García-Valdecasas JC, Fuster J, Charco R, Bombuy E, Fondevila C, Navasa M, Rodríguez-Laiz G, Ferrer J, Amador MA, Llovet JM, Forns X, Rimola A. [Adult living donor liver transplantation. Analysis of the first 30 cases]  Gastroenterol Hepatol  2003;26;9  Link to [Adult living donor liver transplantation. Analysis of the first 30 cases]
  77. Journal Article Burrel M, Llovet JM, Ayuso C, Iglesias C, Sala M, Miquel R, Caralt T, Ayuso JR, Solé M, Sanchez M, Brú C, Bruix J. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation.  Hepatology  2003;38;4  Link to MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation.
  78. Journal ArticleReview Pons-Renedo F, Llovet JM. Hepatocellular carcinoma: a clinical update.  MedGenMed  2003;5;3  Link to Hepatocellular carcinoma: a clinical update.
  79. CommentComparative StudyEditorial Bruix J, Fuster J, Llovet JM. Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision.  Liver Transpl.  2003;9;7  Link to Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision.
  80. Journal ArticleReview Varela M, Sala M, Llovet JM, Bruix J. Review article: natural history and prognostic prediction of patients with hepatocellular carcinoma.  Aliment. Pharmacol. Ther.  2003;17 Suppl 2  Link to Review article: natural history and prognostic prediction of patients with hepatocellular carcinoma.
  81. Journal Article Armengol C, Boix L, Bachs O, Solé M, Fuster J, Sala M, Llovet JM, Rodés J, Bruix J. p27(Kip1) is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma.  J. Hepatol.  2003;38;5  Link to p27(Kip1) is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma.
  82. Journal ArticleReview Varela M, Sala M, Llovet JM, Bruix J. Treatment of hepatocellular carcinoma: is there an optimal strategy?  Cancer Treat. Rev.  2003;29;2  Link to Treatment of hepatocellular carcinoma: is there an optimal strategy?
  83. CommentEditorial Bruix J, Llovet JM. HCC surveillance: who is the target population?  Hepatology  2003;37;3  Link to HCC surveillance: who is the target population?
  84. Journal ArticleMeta-AnalysisReview Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.  Hepatology  2003;37;2  Link to Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.
  85. Journal ArticleReview Bruix J, Llovet JM. Hepatitis B virus and hepatocellular carcinoma.  J. Hepatol.  2003;39 Suppl 1  Link to Hepatitis B virus and hepatocellular carcinoma.
  86. Journal ArticleReview Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects.  J. Hepatol.  2003;38 Suppl 1  Link to Hepatocellular carcinoma: present status and future prospects.

    87. 2002

  87. Journal ArticleReview Forns X, Sánchez Tapias JM, Parés A, Llovet JM, Bruix J, Rodés J. Expected developments in hepatology.  Best Pract Res Clin Gastroenterol  2002;16;6  Link to Expected developments in hepatology.
  88. Journal ArticleReview Llovet JM. Evidence-based medicine in the treatment of hepatocellular carcinoma.  J. Gastroenterol. Hepatol.  2002;17 Suppl 3  Link to Evidence-based medicine in the treatment of hepatocellular carcinoma.
  89. Congresses Sala M, Llovet JM, Bruix J. [Considerations of the Barcelona Conference on the diagnosis and treatment of hepatocellular carcinoma]  Gastroenterol Hepatol  2002;25;9  Link to [Considerations of the Barcelona Conference on the diagnosis and treatment of hepatocellular carcinoma]
  90. Journal ArticleReview Bruix J, Llovet JM. Prognostic assessment and evaluation of the benefits of treatment.  J. Clin. Gastroenterol.  2002;35;5 Suppl 2  Link to Prognostic assessment and evaluation of the benefits of treatment.
  91. Journal Article Forns X, Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, Bruguera M, Sánchez-Tapias JM, Rodés J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model.  Hepatology  2002;36;4 Pt 1  Link to Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model.
  92. Clinical TrialJournal ArticleMulticenter StudyRandomized Controlled Trial Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.  Lancet  2002;359;9319  Link to Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.
  93. Journal ArticleReview Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma.  Hepatology  2002;35;3  Link to Prognostic prediction and treatment strategy in hepatocellular carcinoma.
  94. Journal ArticleReview Llovet JM, Fuster J, Bruix J. Prognosis of hepatocellular carcinoma.  Hepatogastroenterology  2002;49;43  Link to Prognosis of hepatocellular carcinoma.
  95. Journal Article Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E, Rodés J, Bruix J. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation.  Gut  2002;50;1  Link to Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation.

    96. 2001

  96. CommentEditorial Llovet JM, Fuster J. [Liver resection in the treatment of hepatocellular carcinoma]  Gastroenterol Hepatol  2001;24;10  Link to [Liver resection in the treatment of hepatocellular carcinoma]
  97. Journal Article Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.  J. Hepatol.  2001;35;3  Link to Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.
  98. Clinical TrialClinical Trial, Phase IIJournal ArticleMulticenter Study Llovet JM, Ruff P, Tassopoulos N, Castells L, Bruix J, El-Hariry I, Peachey M. A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.  Eur. J. Cancer  2001;37;11  Link to A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.
  99. Journal Article Giménez-Barcons M, Franco S, Suárez Y, Forns X, Ampurdanès S, Puig-Basagoiti F, Sánchez-Fueyo A, Barrera JM, Llovet JM, Bruix J, Sánchez-Tapias JM, Rodés J, Saiz JC. High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis.  Hepatology  2001;34;1  Link to High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis.
  100. Journal ArticleReview Llovet JM, Vilana R, Bianchi L, Brú C. [Radiofrequency in the treatment of hepatocellular carcinoma]  Gastroenterol Hepatol  2001;24;6  Link to [Radiofrequency in the treatment of hepatocellular carcinoma]
  101. Journal Article Llovet JM, Vilana R, Brú C, Bianchi L, Salmeron JM, Boix L, Ganau S, Sala M, Pagès M, Ayuso C, Solé M, Rodés J, Bruix J. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma.  Hepatology  2001;33;5  Link to Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma.
  102. Journal Article Sarasin FP, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A. Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective.  Hepatology  2001;33;5  Link to Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective.
  103. CommentJournal Article Bruix J, Llovet JM. Hepatocellular carcinoma: is surveillance cost effective?  Gut  2001;48;2  Link to Hepatocellular carcinoma: is surveillance cost effective?

    104. 2000

  104. Journal ArticleReview Llovet JM, Bruix J. Early diagnosis and treatment of hepatocellular carcinoma.  Baillieres Best Pract Res Clin Gastroenterol  2000;14;6  Link to Early diagnosis and treatment of hepatocellular carcinoma.
  105. Journal ArticleReview Llovet JM, Sala M, Bruix J. Nonsurgical treatment of hepatocellular carcinoma.  Liver Transpl.  2000;6;6 Suppl 2  Link to Nonsurgical treatment of hepatocellular carcinoma.
  106. Journal Article Llovet JM, Moitinho E, Sala M, Bataller R, Rodríguez-Iglesias P, Castells A, Fernández J, Planas R, Navasa M, Bruix J, Rodés J. Prevalence and prognostic value of hepatocellular carcinoma in cirrhotic patients presenting with spontaneous bacterial peritonitis.  J. Hepatol.  2000;33;3  Link to Prevalence and prognostic value of hepatocellular carcinoma in cirrhotic patients presenting with spontaneous bacterial peritonitis.
  107. CommentLetter Llovet JM, Bruix J. Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma.  Hepatology  2000;32;3  Link to Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma.
  108. Journal ArticleReview Suarez Y, França AC, Llovet JM, Fuster J, Bruix J. The current status of liver transplantation for primary hepatic malignancy.  Clin Liver Dis  2000;4;3  Link to The current status of liver transplantation for primary hepatic malignancy.
  109. CommentComparative StudyEditorialReview Llovet JM, Bruix J, Gores GJ. Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy.  Hepatology  2000;31;4  Link to Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy.
  110. Case ReportsJournal Article Suarez Y, De Lacy AM, Llovet JM. Images in hepatology. Intrahepatic bleeding due to undifferentiated (embryonal) hepatic sarcoma.  J. Hepatol.  2000;32;2  Link to Images in hepatology. Intrahepatic bleeding due to undifferentiated (embryonal) hepatic sarcoma.
  111. Clinical TrialJournal ArticleRandomized Controlled Trial Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, Ayuso C, Vargas V, Rodés J, Bruix J. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma.  Hepatology  2000;31;1  Link to Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma.

    112. 1999

  112. Journal ArticleReview Bruix J, Llovet JM. Locoregional treatments for hepatocellular carcinoma.  Baillieres Best Pract Res Clin Gastroenterol  1999;13;4  Link to Locoregional treatments for hepatocellular carcinoma.
  113. Comparative StudyJournal Article Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation.  Hepatology  1999;30;6  Link to Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation.
  114. Journal ArticleReview Suarez Y, Sala M, Llovet JM, Bruix J. Diagnosis and treatment of hepatocellular carcinoma.  Acta Gastroenterol. Belg.  1999;62;4  Link to Diagnosis and treatment of hepatocellular carcinoma.
  115. Journal Article Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification.  Semin. Liver Dis.  1999;19;3  Link to Prognosis of hepatocellular carcinoma: the BCLC staging classification.
  116. Case ReportsJournal Article Llovet JM, Miquel R. Sclerosing hepatic carcinoma in non-cirrhotic liver resembling metastatic adenocarcinoma.  J. Hepatol.  1999;30;1  Link to Sclerosing hepatic carcinoma in non-cirrhotic liver resembling metastatic adenocarcinoma.
  117. Clinical TrialJournal ArticleRandomized Controlled Trial Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Brú C, Rodés J, Bruix J. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.  Hepatology  1999;29;1  Link to Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.

    118. 1998

  118. Clinical TrialJournal ArticleRandomized Controlled Trial Bruix J, Llovet JM, Castells A, Montañá X, Brú C, Ayuso MC, Vilana R, Rodés J. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution.  Hepatology  1998;27;6  Link to Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution.
  119. Journal Article Llovet JM, Bruix J, Fuster J, Castells A, Garcia-Valdecasas JC, Grande L, Franca A, Brú C, Navasa M, Ayuso MC, Solé M, Real MI, Vilana R, Rimola A, Visa J, Rodés J. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power.  Hepatology  1998;27;6  Link to Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power.
  120. Journal Article Llovet JM, Bartolí R, March F, Planas R, Viñado B, Cabré E, Arnal J, Coll P, Ausina V, Gassull MA. Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: molecular epidemiologic evidence.  J. Hepatol.  1998;28;2  Link to Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: molecular epidemiologic evidence.

    121. 1997

  121. Case ReportsJournal Article Cubiella J, Sans M, Llovet JM, Bustamante J, Ferrer A, Caballeria J, Rodés J. Pulmonary abscess as a complication of transarterial embolization of multinodular hepatocellular carcinoma.  Am. J. Gastroenterol.  1997;92;10  Link to Pulmonary abscess as a complication of transarterial embolization of multinodular hepatocellular carcinoma.
  122. Journal Article Llovet JM, Rodríguez-Iglesias P, Moitinho E, Planas R, Bataller R, Navasa M, Menacho M, Pardo A, Castells A, Cabré E, Arroyo V, Gassull MA, Rodés J. Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes.  J. Hepatol.  1997;26;1  Link to Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes.

    123. 1996

  123. Clinical TrialComparative StudyJournal ArticleMulticenter StudyRandomized Controlled Trial Navasa M, Follo A, Llovet JM, Clemente G, Vargas V, Rimola A, Marco F, Guarner C, Forné M, Planas R, Bañares R, Castells L, Jimenez De Anta MT, Arroyo V, Rodés J. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis.  Gastroenterology  1996;111;4  Link to Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis.
  124. Journal ArticleReview Llovet JM, Bartolí R, Planas R. [Intestinal bacterial translocation]  Gastroenterol Hepatol  1996;19;7  Link to [Intestinal bacterial translocation]
  125. Clinical TrialJournal ArticleMulticenter StudyRandomized Controlled Trial Sánchez-Tapias JM, Forns X, Ampurdanés S, Titó L, Planas R, Viver JM, Acero D, Torres M, Mas P, Morillas R, Forné M, Espinós J, Llovet JM, Costa J, Olmedo E, López-Labrador FX, Jiménez de Anta MT, Rodés J. Low dose alpha interferon therapy can be effective in chronic active hepatitis C. Results of a multicentre, randomised trial.  Gut  1996;38;4  Link to Low dose alpha interferon therapy can be effective in chronic active hepatitis C. Results of a multicentre, randomised trial.
  126. Journal Article Llovet JM, Bartolí R, Planas R, Viñado B, Pérez J, Cabré E, Arnal J, Ojanguren I, Ausina V, Gassull MA. Selective intestinal decontamination with norfloxacin reduces bacterial translocation in ascitic cirrhotic rats exposed to hemorrhagic shock.  Hepatology  1996;23;4  Link to Selective intestinal decontamination with norfloxacin reduces bacterial translocation in ascitic cirrhotic rats exposed to hemorrhagic shock.

    127. 1994

  127. Journal Article Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, Rimola A, Gassull MA, Arroyo V, Rodés J. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis.  Hepatology  1994;20;6  Link to Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis.
  128. Journal Article Llovet JM, Bartolí R, Planas R, Cabré E, Jimenez M, Urban A, Ojanguren I, Arnal J, Gassull MA. Bacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitis.  Gut  1994;35;11  Link to Bacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitis.

    129. 1993

  129. Journal Article Fernández-Bañares F, Esteve-Pardo M, de Leon R, Humbert P, Cabré E, Llovet JM, Gassull MA. Sugar malabsorption in functional bowel disease: clinical implications.  Am. J. Gastroenterol.  1993;88;12  Link to Sugar malabsorption in functional bowel disease: clinical implications.
  130. Journal Article Llovet JM, Planas R, Morillas R, Quer JC, Cabré E, Boix J, Humbert P, Guilera M, Doménech E, Bertrán X. Short-term prognosis of cirrhotics with spontaneous bacterial peritonitis: multivariate study.  Am. J. Gastroenterol.  1993;88;3  Link to Short-term prognosis of cirrhotics with spontaneous bacterial peritonitis: multivariate study.
  131. Journal Article Abad-Lacruz A, Cabré E, González-Huix F, Fernández-Bañares F, Esteve M, Planas R, Llovet JM, Quer JC, Gassull MA. Routine tests of renal function, alcoholism, and nutrition improve the prognostic accuracy of Child-Pugh score in nonbleeding advanced cirrhotics.  Am. J. Gastroenterol.  1993;88;3  Link to Routine tests of renal function, alcoholism, and nutrition improve the prognostic accuracy of Child-Pugh score in nonbleeding advanced cirrhotics.

    132. 1991

  132. CommentLetter Fernandez-Bañares F, Esteve-Pardo M, Humbert P, de Leon R, Llovet JM, Gassull MA. Role of fructose-sorbitol malabsorption in the irritable bowel syndrome.  Gastroenterology  1991;101;5  Link to Role of fructose-sorbitol malabsorption in the irritable bowel syndrome.
  133. English AbstractJournal Article Bertrán X, Fernández-Bañares F, Planas R, Cabré E, Morillas R, De León R, Guilera M, Quer JC, Llovet JM, Doménech E. [Impact on the energetic-proteic nutritional status of total paracentesis combined with infusion of albumin or dextran-70 in the therapy of tension ascites in liver cirrhosis]  Rev Esp Enferm Dig  1991;79;5  Link to [Impact on the energetic-proteic nutritional status of total paracentesis combined with infusion of albumin or dextran-70 in the therapy of tension ascites in liver cirrhosis]
  134. Clinical TrialEnglish AbstractJournal ArticleRandomized Controlled Trial Quer JC, Boix J, Planas R, Domínguez M, Abad-Lacruz A, Humbert P, Morillas R, Guilera M, Llovet JM, Gassull MA. [Prophylactic sclerosis of esophageal varices. Results of a controlled prospective study]  Med Clin (Barc)  1991;96;7  Link to [Prophylactic sclerosis of esophageal varices. Results of a controlled prospective study]
  135. English AbstractJournal Article Seguí J, Cascio A, Aragón C, Llovet JM, Soler JM, Salvador L. [Subgroups of drug abuse patients who consume buprenorphine]  An Med Interna  1991;8;1  Link to [Subgroups of drug abuse patients who consume buprenorphine]
Back to page of Llovet, Josep M..

Due mainly to homonyms, errors are possible and if you detect "false positives" or "false negatives" don't be too frustrated and please contact the webmaster.